Posted inGastroenterology news OB/GYN & Women’s Health
Postmarketing Data Link Fezolinetant Primarily to Early Transaminase Elevations Rather Than Overt Liver Injury
FAERS postmarketing data suggest fezolinetant is associated with an early hepatic adverse event reporting signal, driven mainly by liver enzyme elevations rather than consistent severe clinical liver injury.